United States · Platforms & data · The Motley Fool

Novartis: 3 Key Takeaways for Long-Term Investors

Published by The Motley Fool · United States 1 h ago

Operating margins are on track to hit 40% by 2029 as cost discipline accelerates alongside new drug launches.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

CRC outlines 2027 $450M-$475M 6-rig California plan while targeting San Pablo Bay restart in Q1 2027

Curaleaf (OTCMKTS:CURLF) Announces Earnings Results

Here’s why AMD’s stock is rising — and sending a confident message about the AI trade

NPK International director John Minge buys $138,600 in shares

Stock market after midterm elections: What S&P 500 history shows

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030